Raymond E. Cabillot Sells 5,381 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) Director Raymond E. Cabillot sold 5,381 shares of the stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $41.64, for a total transaction of $224,064.84. Following the completion of the transaction, the director now directly owns 319,752 shares of the company's stock, valued at $13,314,473.28. This trade represents a 1.66 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Pro-Dex Stock Up 1.3 %

Shares of Pro-Dex stock traded up $0.52 on Tuesday, reaching $41.79. 20,432 shares of the company were exchanged, compared to its average volume of 27,696. Pro-Dex, Inc. has a one year low of $16.18 and a one year high of $59.60. The company has a current ratio of 3.41, a quick ratio of 1.94 and a debt-to-equity ratio of 0.36. The company has a 50-day moving average of $47.75 and a 200 day moving average of $34.11. The company has a market capitalization of $136.24 million, a price-to-earnings ratio of 27.14 and a beta of 0.56.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP boosted its stake in shares of Pro-Dex by 5.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier's stock valued at $1,238,000 after purchasing an additional 3,067 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Pro-Dex by 9.1% in the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier's stock worth $819,000 after acquiring an additional 2,296 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier's stock valued at $740,000 after purchasing an additional 529 shares during the last quarter. Bard Associates Inc. grew its holdings in Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier's stock worth $406,000 after acquiring an additional 2,031 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in Pro-Dex by 7.9% in the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier's stock valued at $240,000 after buying an additional 900 shares during the period. 15.28% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on PDEX shares. StockNews.com upgraded Pro-Dex from a "buy" rating to a "strong-buy" rating in a research note on Saturday, December 14th. Ascendiant Capital Markets raised their price target on Pro-Dex from $30.00 to $52.00 and gave the stock a "buy" rating in a research report on Monday, November 11th.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.